Navigation Links
ViroPharma to Present at Several Upcoming Healthcare Conferences
Date:9/3/2009

EXTON, Pa., Sept. 3 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the company will be presenting in four upcoming healthcare investment conferences during the month of September.

Charles Rowland, vice president and chief financial officer of ViroPharma, will present at the Rodman & Renshaw 11th Annual Global Healthcare Conference at 11:15 A.M. ET on Thursday, September 10, 2009. The conference is being held at the New York Palace Hotel.

Vincent Milano, president and chief executive officer of ViroPharma, will present at the Thomas Weisel Partners 2009 Global Healthcare Conference at 8:00 A.M. ET on Thursday, September 10, 2009. The conference is being held at the Four Seasons Hotel in Boston.

William Roberts, vice president, corporate communications will present at the BioCentury Newsmakers in the Biotech Industry Conference at 3:30 P.M. ET on Wednesday, September 16, 2009. The conference is being held at the Millennium Broadway Hotel in New York City.

Mr. Milano will also present at the ThinkEquity 6th Annual Growth Conference at 5:15 P.M. ET (2:15 P.M. PT) on Wednesday, September 16, 2009. The conference is being held at the St. Regis Hotel in San Francisco.

ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. ViroPharma commercializes Cinryze(TM) (C1 esterase inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.

ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema
2. ViroPharma to Present at Two June Healthcare Conferences
3. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
4. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
5. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
6. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
7. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
8. ViroPharma to Present at Three November Healthcare Conferences
9. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
10. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
11. ViroPharma to Present at Three October Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... Genedata, a leading provider ... the occasion with a strong presence at Bio-IT World Conference & Expo 2017 ... an invitation to all attendees to view posters on the entire range ...
(Date:5/23/2017)... , ... May 23, 2017 , ... ... as Vice President of Clinical Operations. She brings years of expertise in ... Therapeutics. From her professional foundation as a licensed occupational therapist, through a variety ...
(Date:5/22/2017)... (PRWEB) , ... May 22, 2017 , ... ... joined with other leaders of the Maryland Biohealth community in developing and issuing ... recognized Top 3 U.S. BioHealth Innovation Hub by 2023. , ...
(Date:5/19/2017)... ... May 19, 2017 , ... The University City ... with technologies ripe for commercialization, and who are affiliated with the 21 partner ... submit proposals. QED, now in its tenth round, is the first multi-institutional proof-of-concept ...
Breaking Biology Technology:
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
(Date:4/4/2017)... 4, 2017   EyeLock LLC , a leader ... United States Patent and Trademark Office (USPTO) has issued ... linking of an iris image with a face image ... the company,s 45 th issued patent. ... timely given the multi-modal biometric capabilities that have recently ...
Breaking Biology News(10 mins):